A hit and a miss with pegcetacoplan in late-stage trials leaves Apellis with shrinking prospects.
But questions remain about both the Norse Two trial and the commercial opportunity.
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
Abbvie expects more Rinvoq data in ulcerative colitis while Astrazeneca takes on myasthenia gravis, and gene therapy is in play for Pfizer and Roche.
Pivotal development of GEM103 is set to proceed, but the phase 2 result is a cautionary tale – not only for Gemini.
But data are early, and other groups are also developing less frequent injections for wet AMD.